1.
Zhang LL, Wei JY, Wang L, Huang SL, Chen JL. Human T-cell lymphotropic virus type 1 and its oncogenesis. Acta Pharmacol Sin. 2017;38(8):1093-103. doi: 10.1038/aps.2017.17. [PubMed: 28392570]. [PubMed Central: PMC5547553].
2.
Goncalves DU, Proietti FA, Ribas JG, Araujo MG, Pinheiro SR, Guedes AC, et al. Epidemiology, treatment, and prevention of human T-cell leukemia virus type 1-associated diseases. Clin Microbiol Rev. 2010;23(3):577-89. doi: 10.1128/CMR.00063-09. [PubMed: 20610824]. [PubMed Central: PMC2901658].
3.
Koech CC, Lwembe RM, Odari EO, Budambula NLM. Prevalence and associated risk factors of HTLV/HIV co-infection among people who inject drugs (PWIDs): A review. J Hum Virol Retrovirol. 2018;6(1):188.
4.
Fujino T, Nagata Y. HTLV-I transmission from mother to child. J Reprod Immunol. 2000;47(2):197-206. doi: 10.1016/s0165-0378(00)00054-1.
5.
Proietti FA, Carneiro-Proietti ABF, Catalan-Soares BC, Murphy EL. Global epidemiology of HTLV-I infection and associated diseases. Oncogene. 2005;24(39):6058-68. doi: 10.1038/sj.onc.1208968. [PubMed: 16155612].
6.
Rowhani-Rahbar A, Yazdi Tabatabaei A, Panahi M. Prevalence of common blood-borne infections among imprisoned injection drug users in Mashhad, North-East of Iran. Arch Iranian Med. 2004;7(3):190-4.
7.
Aceijas C, Stimson GV, Hickman M, Rhodes T, Care among I. D. U. in Developing Transitional Countries ; United Nations Reference Group on H. I. V. Aids Prevention. Global overview of injecting drug use and HIV infection among injecting drug users. AIDS. 2004;18(17):2295-303. doi: 10.1097/00002030-200411190-00010. [PubMed: 15577542].
8.
Scheidegger C, Zimmerli W. Infectious complications in drug addicts: Seven-year review of 269 hospitalized narcotics abusers in Switzerland. Rev Infect Dis. 1989;11(3):486-93. [PubMed: 2749105].
9.
Mortezaie Z, Bouzari M, Roghanian R. Evaluating the frequency of HTLV-Ι/II infection among blood donors, major thalassemic patients and individuals infected with hepatitis B and C viruses in Isfahan, Iran. Iran J Blood Canc. 2012;4(1):169-75.
10.
Ghafouri M, Ameli MR. [Comparing prevalence of transfusion transmitted viral infections in various population groups of South Khorasan]. Sci J Iran Blood Transfus Org (Khoon). 2011;7(4):242-68. Persian.
11.
Hedayati MMR. [Seroepidemiology of human T-cell lymphotropic virus type 1 infection in Iran: An overview]. J Med Counc I.R.I. 2013;30(4):367-8. Persian.
12.
Khajedaluee M, Babaei A, Vakili R, Valizade N, Homaei Shandiz F, Alavian SM, et al. Sero-prevalence of bloodborne tumor viruses (HCV, HBV, HTLV-I and KSHV infections) and related risk factors among prisoners in Razavi Khorasan province, Iran, in 2008. Hepat Mon. 2016;16(12). e31541. doi: 10.5812/hepatmon.31541. [PubMed: 28123439]. [PubMed Central: PMC5237471].
13.
Prasetyo AA, Dirgahayu P, Sari Y, Hudiyono H, Kageyama S. Molecular epidemiology of HIV, HBV, HCV, and HTLV-1/2 in drug abuser inmates in central Javan prisons, Indonesia. J Infect Dev Ctries. 2013;7(6):453-67. doi: 10.3855/jidc.2965. [PubMed: 23771289].
14.
Catalan-Soares BC, Almeida RTP, Carneiro-Proietti ABF. Prevalence of HIV-1/2, HTLV-I/II, hepatitis B virus (HBV), hepatitis C virus (HCV), Treponema pallidum and Trypanosoma cruzi among prison inmates at Manhuacu, Minas Gerais State, Brazil. Rev Soc Bras Med Trop. 2000;33(1):27-30. [PubMed: 10881115].
15.
Ziaee M, Namaei MH, Azarkar G. The prevalence of HTLV-1 and its co-infection with HCV, HBV and HIV in hemophilic patients. Pak J Med Sci. 2015;31(5):1246-9. doi: 10.12669/pjms.315.7888. [PubMed: 26649023]. [PubMed Central: PMC4641292].
16.
Namaei MH, Azizee R, Ziaee M. Prevalence of HCV infection in hemodialysis patients of South Khorasan in comparison with HBV, HDV, HTLV I/II, and HIV infection. Bangladesh J Med Sci. 2013;13(1):36-9. doi: 10.3329/bjms.v13i1.13903.
17.
Cantor KP, Weiss SH, Goedert JJ, Battjes RJ. HTLV-I/II seroprevalence and HIV/HTLV coinfection among U.S. intravenous drug users. J Acquir Immune Defic Syndr. 1991;4(5):460-7. [PubMed: 2016683].
LEAVE A COMMENT HERE: